Cargando…
Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule
Apremilast, an orally administered small molecule inhibitor of phosphodiesterase 4 (PDE4), has been licensed by the US Food and Drug Administration for the management of active psoriatic arthritis (March 21, 2014) and moderate to severe plaque psoriasis (September 23, 2014). It has got approval from...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362739/ https://www.ncbi.nlm.nih.gov/pubmed/30775293 http://dx.doi.org/10.4103/idoj.IDOJ_437_18 |
_version_ | 1783392989136027648 |
---|---|
author | Afra, T. P. Razmi, T Muhammed Dogra, Sunil |
author_facet | Afra, T. P. Razmi, T Muhammed Dogra, Sunil |
author_sort | Afra, T. P. |
collection | PubMed |
description | Apremilast, an orally administered small molecule inhibitor of phosphodiesterase 4 (PDE4), has been licensed by the US Food and Drug Administration for the management of active psoriatic arthritis (March 21, 2014) and moderate to severe plaque psoriasis (September 23, 2014). It has got approval from Drug Controller General of India for marketing in India in 2017. The drug has drawn much attention from the practising dermatologists for its commendable safety profile and prescription convenience. Introduced initially as an orally administered small molecule in psoriasis patients, the drug has now been used in various other indications as evident by the recent surge in literature for its off-label uses. Being a relatively new drug in the treatment armamentarium of psoriasis and other inflammatory dermatoses; in this review, we will discuss various practical aspects of prescribing oral apremilast, based on the current and emerging literature. |
format | Online Article Text |
id | pubmed-6362739 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-63627392019-02-17 Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule Afra, T. P. Razmi, T Muhammed Dogra, Sunil Indian Dermatol Online J Review Article Apremilast, an orally administered small molecule inhibitor of phosphodiesterase 4 (PDE4), has been licensed by the US Food and Drug Administration for the management of active psoriatic arthritis (March 21, 2014) and moderate to severe plaque psoriasis (September 23, 2014). It has got approval from Drug Controller General of India for marketing in India in 2017. The drug has drawn much attention from the practising dermatologists for its commendable safety profile and prescription convenience. Introduced initially as an orally administered small molecule in psoriasis patients, the drug has now been used in various other indications as evident by the recent surge in literature for its off-label uses. Being a relatively new drug in the treatment armamentarium of psoriasis and other inflammatory dermatoses; in this review, we will discuss various practical aspects of prescribing oral apremilast, based on the current and emerging literature. Medknow Publications & Media Pvt Ltd 2019 /pmc/articles/PMC6362739/ /pubmed/30775293 http://dx.doi.org/10.4103/idoj.IDOJ_437_18 Text en Copyright: © 2019 Indian Dermatology Online Journal http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Review Article Afra, T. P. Razmi, T Muhammed Dogra, Sunil Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule |
title | Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule |
title_full | Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule |
title_fullStr | Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule |
title_full_unstemmed | Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule |
title_short | Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule |
title_sort | apremilast in psoriasis and beyond: big hopes on a small molecule |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362739/ https://www.ncbi.nlm.nih.gov/pubmed/30775293 http://dx.doi.org/10.4103/idoj.IDOJ_437_18 |
work_keys_str_mv | AT afratp apremilastinpsoriasisandbeyondbighopesonasmallmolecule AT razmitmuhammed apremilastinpsoriasisandbeyondbighopesonasmallmolecule AT dograsunil apremilastinpsoriasisandbeyondbighopesonasmallmolecule |